z-logo
open-access-imgOpen Access
Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors
Author(s) -
Wu Qiuji,
Chu Qian,
Zhang Hongyan,
Yang Bin,
He Xudong,
Zhong Yahua,
Yuan Xianglin,
Chua Melvin L.K.,
Xie Conghua
Publication year - 2020
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1002/cac2.12077
Subject(s) - covid-19 , immune checkpoint , disease , medicine , coronavirus , immune system , cancer , oncology , immunotherapy , virology , immunology , infectious disease (medical specialty) , outbreak
Dear Editor, The coronavirus disease 2019 (COVID-19) pandemic has affected over 6,000,000 people globally [1]. Patients with COVID-19 manifest with symptoms of fever, dry cough, dyspnea, and present with radiological changes that are consistent with atypical pneumonia [2]. Pathogenetic mechanisms for these abnormalities involve the systemic immune response that is associated with the hyperactivation of peripheral CD8 and CD4 T cells, and a cytokine storm [3]. Globally, the reported prevalence of patients with COVID-19 and cancer ranges from 0.5% to 6.0% in the different case series [4]. Consistent with these studies, we had previously reported that patients with cancer harbored an approximately 2-fold higher risk of COVID-19 than non-cancer patients, thereby indicating that this group of patients represents a susceptible population [5]. Immune checkpoint inhibitors (ICI) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1) immuno-inhibitory axis have demonstrated single-agent activity in treatment-refractory cancers, and have also demonstrated synergism with chemotherapy and radiotherapy in the first-line setting [6]. Anti-CTLA-4 and anti-PD-1/-PD-L1 antibodies work by targeting the T-cell exhaustion pathways, thereby resulting in reactivation of cytotoxic CD8 T cells for antitumor activity [6]. Given the convergence of the downstream effects on the innate immunity by both ICI and severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infections, we therefore queried whether patients with cancer and prior exposure to ICI would present with

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here